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A logistic regression analysis of risk factors
in ME/CFS pathogenesis
Eliana M. Lacerda1* , Keith Geraghty2, Caroline C. Kingdon1, Luigi Palla1 and Luis Nacul1
Abstract
Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex disease, whose exact
cause remains unclear. A wide range of risk factors has been proposed that helps understanding potential disease
pathogenesis. However, there is little consistency for many risk factor associations, thus we undertook an
exploratory study of risk factors using data from the UK ME/CFS Biobank participants. We report on risk factor
associations in ME/CFS compared with multiple sclerosis participants and healthy controls.
Methods: This was a cross-sectional study of 269 people with ME/CFS, including 214 with mild/moderate and 55
with severe symptoms, 74 people with multiple sclerosis (MS), and 134 healthy controls, who were recruited from
primary and secondary health services. Data were collected from participants using a standardised written
questionnaire. Data analyses consisted of univariate and multivariable regression analysis (by levels of proximity to
disease onset).
Results: A history of frequent colds (OR = 8.26, P <= 0.001) and infections (OR = 25.5, P = 0.015) before onset were
the strongest factors associated with a higher risk of ME/CFS compared to healthy controls. Being single (OR = 4.41,
P <= 0.001), having lower income (OR = 3.71, P <= 0.001), and a family history of anxiety is associated with a higher
risk of ME/CFS compared to healthy controls only (OR = 3.77, P < 0.001). History of frequent colds (OR = 6.31, P <
0.001) and infections before disease onset (OR = 5.12, P = 0.005), being single (OR = 3.66, P = 0.003) and having
lower income (OR = 3.48, P = 0.001), are associated with a higher risk of ME/CFS than MS. Severe ME/CFS cases were
associated with lower age of ME/CFS onset (OR = 0.63, P = 0.022) and a family history of neurological illness
(OR = 6.1, P = 0.001).
Conclusions: Notable differences in risk profiles were found between ME/CFS and healthy controls, ME/CFS and
MS, and mild-moderate and severe ME/CFS. However, we found some commensurate overlap in risk associations
between all cohorts. The most notable difference between ME/CFS and MS in our study is a history of recent
infection prior to disease onset. Even recognising that our results are limited by the choice of factors we selected to
investigate, our findings are consistent with the increasing body of evidence that has been published about the
potential role of infections in the pathogenesis of ME/CFS, including common colds/flu.
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Background
Myalgic Encephalomyelitis (ME) was originally described
as a post-infectious disease causing malaise, muscle
weakness, and nervous system complaints, primarily
pain, cognitive dysfunction, and sleep disturbance [1].
Chronic fatigue syndrome (CFS) is an alternative label
introduced in the late 1980s to describe a pattern of
symptoms, specifically unexplained fatigue [2]. The two
names are often used synonymously. ME/CFS prevalence
rates vary widely across studies, but a rate between 0.2
and 0.5% is commonly reported for adults [3]. A number
of different diagnostic criteria are used to identify poten-
tial cases. In the UK, the National Institute for Health
and Care Excellence (NICE) has recommended a diagno-
sis after 6 months of persistent unexplained fatigue, not
relieved by rest, which results in a substantial loss of
normal physical or social function [4]. The US Centre
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: Eliana.lacerda@lshtm.ac.uk
1Faculty of Infectious and Tropical Diseases, London School of Hygiene &
Tropical Medicine, London WC1E 7HT, UK
Full list of author information is available at the end of the article
Lacerda et al. BMC Neurology          (2019) 19:275 
https://doi.org/10.1186/s12883-019-1468-2
for Disease Control (CDC) criteria from 1994 require a
wider set of characteristic symptoms [5], whilst other
criteria require the presence of post-exertional malaise [6].
The aetiology and pathogenesis of ME/CFS remains con-
tested but many patients recount their symptoms starting
after an infection and an increasing number of studies find
neuro-immunological and cellular abnormalities that sup-
port an association between infection and pro-
inflammatory immune alterations in ME/CFS [7, 8].
A range of disparate risk factors has been proposed as
disease-specific. A number of studies suggest a higher
prevalence of ME/CFS among family members, particu-
larly twins [9], suggesting a genetic heritability risk factor.
Underhill and O’Gorman found that 20.5% of members of
a US CFS sample, reported a family member with CFS
(18% being blood relatives), suggesting a strong genetic
predisposition [10]. A genetic study has found a number
of DNA single-nucleotide polymorphisms (SNPs) from
over 906,600 known SNPs analysed from ME/CFS sub-
jects, and identified 442 potential loci that might be asso-
ciated with ME/CFS [11]. Despite the small sample size,
this study exemplifies the vast complexity of genes as a
risk factor in ME/CFS. The relative-risk attached to such
factors is difficult to ascertain from a review of the litera-
ture. A systematic scoping review by Hempel et al. ana-
lysed risk factors for ME/CFS using multiple predictors
[12], but from 10,768 relevant publications, only 11 met
inclusion criteria. Hempel et al. concluded that there was
poor replication of risk factors across multiple studies, so
that few demographic, medical, psychological, social and
environmental factors can be considered suitable predict-
ive indicators in clinical practice. A major problem in the
studies reviewed is the variability of diagnostic criteria
used (including in self-reported ME/CFS) and a lack of
consistent methodology. The most credible risk factors for
ME/CFS onset are sex, with a higher female to male ratio
[13] and a history of infection [14], the latter highlighting
the importance of environmental factors in the aetiology
of ME/CFS, which may act independently or interact with
genetic risk factors. Large population datasets have been
used to explore pre-morbid health factors and ME/CFS.
There is some evidence of a link between affective disor-
ders (anxiety and depression) and ME/CFS while work on
pre-morbid activity levels has not been able to establish a
firm link with prior levels of physical activity. A link
between CFS and childhood abuse has been suggested,
although results from case-control studies have been
contradictory [15, 16].
The need to further explore and assess risk factors for
ME/CFS prompted this study, which investigates poten-
tial risk factors by comparing data from a cohort of the
UK ME/CFS Biobank (UKMEB) participants. This co-
hort includes people with ME/CFS, people with multiple
sclerosis (MS), and healthy controls.
Methods
The UKMEB team has collected patient data and bio-
logical samples from informed consenting participants
since 2012. Recruitment procedures for the UKMEB
have been exemplified elsewhere, in a publication that
also lists the data collection instruments used [17]. Re-
cruitment for the UKMEB cohort included the invitation
of potential participants by collaborating NHS Services
(primary and secondary care), who used their databases
to identify people diagnosed with ME/CFS, people diag-
nosed with MS, and potential healthy controls, aged be-
tween 18 and 60 years. The NHS Services sent out
invitation packs provided by the research team contain-
ing an invitation letter from the health service with in-
formation about the study (with specific information
sheets for cases and controls), a consent form, a ques-
tionnaire to assess symptoms, and a refusal form. People
with ME/CFS who are bed- or home-bound are often
unable to attend the NHS services, and were invited by
support groups. Health services and higher education in-
stitutions such as the LSHTM, also handed invitation
packs for potential healthy controls.
Once signed consent forms and questionnaires had
been assessed by the research team, those who had a
likely diagnosis of ME/CFS according to the research
criteria (CDC-1994 [5] or Canadian Consensus Cri-
teria [6]) and who were able to travel were invited to a
recruiting centre by the research team, while those
with severe disease and mobility restrictions were vis-
ited at home by a clinical researcher. Participants were
excluded if they had: i) used drugs known to alter
immune function (e.g. azathioprine, cyclosporine,
methotrexate, steroids), anti-viral medications and
vaccinations in the 3 months prior to recruitment; or
ii) a history of acute or chronic infectious diseases
such as hepatitis B and C, tuberculosis, HIV (but not
herpes virus or other retrovirus infection); iii) a his-
tory of other severe illness (such as cancer, coronary
heart disease, or uncontrolled diabetes), and/or and
severe mood disorders, iv) a history of illicit drug use;
and/or v) a BMI ≥ 40. Pregnant women and those
within 12 months post-partum and/or currently lactat-
ing were also excluded. Those people who had offered
to take part but were ineligible were thanked by the
research manager and a full explanation of the reason
was given.
At the clinical appointment, all participants were ex-
amined by a health professional; the diagnosis of ME/
CFS for research purposes was reached only after this
assessment and following the results of the clinical blood
tests taken, which were aimed to exclude other condi-
tions that could explain chronic fatigue. All participants
with MS had a prior diagnosis from a UK NHS neur-
ology consultant according to NHS guidelines [18].
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We invited 2430 individuals identified by our collaborat-
ing NHS services (942 with ME/CFS, 278 with MS and
1210 healthy), in addition to 112 people with a confirmed
medical diagnosis of ME/CFS invited by ME/CFS support
groups, of whom 84 invited healthy individuals to act as
controls. Of the total potential participants invited, 138
declined to participate (45 had a possible diagnosis of ME/
CFS, 26 MS, 48 healthy controls; 19 received refusal forms
were incomplete) and 1828 were non-respondents. The
distribution by sex and age group of those who declined
to participate in all groups, was similar to the groups of
those recruited, and the proportion of stated refusals
was similar across the recruiting health services varying
between 4 and 10% (median 6.3%, IQR 5.3 to 8.9%).
From the consenting potential participants, 660 were
assessed for eligibility as previously described, of which
532 were recruited. After additional exclusions, per
study protocol, the final cohort considered in this paper
includes ME/CFS participants with mild/moderate (n-
214), and with severe symptoms (n-55), participants
with MS (n-74), and healthy controls (n-134).
Data analysis
UKMEB participant questionnaire responses [17] were
grouped under the following headings: socio-economic,
demographic, family health history, lifestyle, co-morbidities,
and other potential risk factors associated with ME/CFS
(See Additional file 1). All these were self-reported, as we
did not have access to their medical records to further ex-
plore the presence of these risk factors. Due to the cross
sectional design of the study, with control groups (where
controls are either healthy or MS subjects), logistic regres-
sion was used for prediction (binary outcome, logit link,
structural linear model, with model parameters estimated
by maximum likelihood). Because of the limited sample size
/ number of cases and the presence of a large number of
predictors within a logistic regression prediction model, the
framework used for analysis considered separate variable
domains for prediction of the outcome (ME/CFS cases)
versus one of the two comparison groups (i.e. people with
MS, and healthy controls), in order to select the predictors.
The analysis framework was inspired by a conceptual ap-
proach to risk factor modelling according to which risk fac-
tors can be separated into distinct hierarchical levels
relative to the outcome [18].
After running univariate logistic regression analyses for
each putative risk factor in all domains (Table 1), we in-
cluded in the multivariable logistic regression models
those factors that showed a statistically significant differ-
ence with the comparison group (P ≤ 0.10). The following
variables from the recent exposures domain ‘immunisa-
tions’ and ‘BCG vaccination’ were later aggregated as one
variable named ‘immunisation(s) before onset’; likewise,
‘meningitis’ and ‘other serious infection’, were aggregated
into a new variable named ‘infection(s) before onset’. Sub-
sequently, we ran the multivariable models, starting with
the more distal domain (demographic) and working to-
wards the proximate domain (recent exposures) to the
outcome. The model selection strategy was to add all the
variables of the subsequent domain and, in a step-wise
manner, remove those whose likelihood ratio test (com-
paring reduced and full model) had P-value> 0.05. The
overall model fit (Pearson chi squared test, pseudo R
squared) and predictive ability (sensitivity/specificity, cor-
rect classification rate) were also assessed for all models.
The analyses were conducted with complete cases. The
analyses were performed with Stata 15.1 [20].
Results
We found a 3:1 female to male ratio in our ME/CFS and
MS participant groups; however, the female/male ratio
Table 1 List of variables used in the univariate logistic regression
analyses with all comparison groups, organised by domains
Domains List of variables
Demographic Age at survey (or age at disease
onset for the diseased groups),
sex, ethnicity.
Socio-economic Marital status, education,
individual income, index of
multiple deprivationa.
Family health history High blood pressure, diabetes,
heart problems, asthma, allergies,
depression, anxiety, mental health
problems, learning disabilities,
physical disabilities, cancer, ME/CFS,
MS, other neurological problems,
tuberculosis, any other health
problems.
Lifestyle Smoking status, alcohol
consumption/week, physical
activity
Previous morbidity
(prior to disease onset)
High blood pressure, heart
problems, asthma, allergies,
depression, anxiety, high levels
of stress, history of frequent
coughs/colds, intolerance to
alcoholic drinks, intolerance to
sugar, other health problems.
Recent exposures (6 months
prior to disease onset)
Lived on a farm, tick bites,
vaccines/immunisations,
travelling overseas, flooding,
radiation, carbon monoxide (CO),
pesticides, any other chemicals,
had meningitis, had any other
serious infection, had any head
injury, had a major operation,
contraceptive pill (women only),
lived in a house with gas or oil
appliances (for heating or cooking),
lived in a house with a gas fire,
BCG vaccination.
ME/CFS Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, MS
Multiple Sclerosis.
aIndex of multiple deprivation refers to area of residence [19]. All other
variables are as reported by research participants
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in the healthy control group was 1.5:1 (P = 0.011). The
age group distribution was similar among the healthy
and ME/CFS groups (P = 0.943); the MS group had a
higher proportion of individuals over 30 years of age
(P = 0.002). The most common ethnicity reported by
participants in all groups was white British (> 90%), with
the groups of ME/CFS with severe symptoms and of
healthy controls reporting a slightly more diverse ethnic
background which still amounted to a small proportion
of participants (< 10%).
In Table 2 we present a description of participants
from the UK ME/CFS Biobank, by category of recruit-
ment and each distinct domain, containing distinct sets
of variables.
Table 3 shows the variables associated with the out-
come in each domain level (P < 0.10), with comparisons
between ME/CFS cases and healthy controls, and ME/
CFS and MS cases.
From the multivariable logistic regression analysis for
each of the comparisons, we found that compared to
healthy controls, participants with ME/CFS were less
likely to be in a relationship (be single), more likely to
have a lower income, to report a family history (but not
a personal history) of anxiety, and to report frequent
colds and coughs, and infections in the 6 months prior
to disease onset (Table 4). The model fit statistics re-
sulted in Pearson chi-square P = 0.80 and pseudo R
squared = 0.33, 78% of individuals correctly classified,
sensitivity of 83% and specificity of 71%. Similarly, by
comparing ME/CFS and MS participants, we found
increased risks of ME/CFS related to not being in a
relationship, have a lower income, have a history of pre-
disposition to colds and coughs, and to having an infec-
tious disease in the 6 months before disease onset
(Table 5). This model had worse model fit statistics with
Pearson chi-square P = 0.004 and pseudo R squared =
0.26, 82% of individuals correctly classified, sensitivity of
95% and specificity of 34%.
Those with severe ME/CFS were more likely to be
younger; 15 of these participants reported a family his-
tory of neurological problems, of which the most com-
monly reported were stroke (4) and Parkinson’s disease
(3/15); 9/15 reported that their father was affected and
4/15, their mother. Of the 9 people with mild-moderate
ME/CFS who reported neurological family problems, 4
of those reported had a family history of dementia, 5
reported that it was their mother who was affected.
Discussion
Our recruited UKMEB cohort reflects the predominance of
ME/CFS and MS in females that has been reported in the
literature. There is consistent evidence for a higher rate of
ME/CFS among girls and women [21], with rates among
girls increasing above those of boys post-puberty [22]. A
Spanish study of disease epidemiology among 1309 CFS
patients meeting the Fukuda criteria found a 90% female
dominance [23], however ratios between 2:1 to 4:1 are often
reported [3]. This female dominance is not uncommon in
autoimmune diseases; MS affects more women than men
in a similar ratio [24]. In terms of epidemiological and
neuro-immune characteristics, associations have been
drawn between ME/CFS and MS, fibromyalgia, and
rheumatoid arthritis [25]. However, we also must consider
that the majority of our cohort was recruited from primary/
secondary care services, which have been reported to have
higher attendance of females, particularly between 16 and
60 years of age, when the gender gap was observed in the
UK [26], The gender differences for health care seeking
varies greatly across populations [26, 27], and we must take
these variations into account when interpreting study re-
sults that recruit from health services.
ME/CFS v healthy controls
Most participants with ME/CFS anecdotally report their ill-
ness started after an infection [28] and our study affirms
the importance of infection as a strong risk factor for ME/
CFS onset. Our findings indicate that a history of frequent
colds and infection in the 6 months preceding disease onset
is associated with a higher risk of ME/CFS, compared with
healthy controls and participants with MS. Research has
shown that ME/CFS is linked with exposure to Epstein–
Barr virus, Coxsackie B, Human Herpes virus 6 and 7, and
Coxiella burnetii [14, 29, 30], with stronger associations
with infections in those with more severe acute response to
infections [31]. Chia and Chia proposed a link between
ME/CFS and enterovirus infection after the biopsies from
135/165 CFS patients (82%) stained positive for VP1 within
parietal cells, versus just 7/34 (20%) of healthy controls
[32]. There is scant research linking ME/CFS to the com-
mon cold or flu-like infections, though upper respiratory
infections are often reported as preceding the development
of disabling fatigue in clinical practice. Our findings suggest
a risk association, based on self-report. Clark et al. found a
history of colds in childhood (at age 7 or 11) increased the
risk of ME/CFS later in life (ORs ranged from 1.6 to 1.9)
[33]. The predictive role of pre-morbid stress and infection
is frequently reported in ME/CFS [34]. The exact cumula-
tive impact of these two factors is uncertain, although it is
well established that chronic stress has a considerable de-
pressive effect on immune status, perhaps rendering an in-
dividual more susceptible to chronic infection. It is known
that herpes viruses (HSV1 and HSV2, HHV6) are associ-
ated with a range of acute and chronic illnesses including,
encephalitis/meningitis, shingles, chicken pox (Varicella
Zoster), mononucleosis (Epstein Barr Virus), Kaposi’s sar-
coma (HHV8); and hearing loss, mental retardation with
cytomegalovirus (HMCV) [30, 35]. Viral infections may dis-
rupt mitochondrial function, resulting in fatigue; a cardinal
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Table 2 Description of participants from the UK ME/CFS Biobank, by category of recruitment and variables under the following
domains: demographic, socio-economic, family health history, lifestyle, previous morbidity (prior disease onset for the diseased
groups), and recent exposures
Domains Variables Category of Recruitment Total
Healthy
control
MS control ME/CFSmm
(n) (%) (n) (%) (n) (%) (n) (%)
Demographic Sex Male 51 38.1 16 21.6 63 23.4 130 27.3
Female 83 61.9 58 78.4 206 76.6 347 72.7
Age group >=18 & <30 22 16.4 1 1.4 43 16.0 66 13.8
>=30 & <40 33 24.6 12 16.2 60 22.3 105 22.0
>=40 & <50 35 26.1 18 24.3 75 27.9 128 26.8
>=50 & <=60 44 32.8 43 58.1 91 33.8 178 37.3
Incidence age group <18 n/a n/a 3 4.2 42 16.7 45 14.0
>=18 & <30 n/a n/a 19 26.8 88 35.1 107 33.2
>=30 & <40 n/a n/a 22 31.0 61 24.3 83 25.8
>=40 & <50 n/a n/a 22 31.0 49 19.5 71 22.0
>=50 & <=60 n/a n/a 5 7.0 11 4.4 16 5.0
Ethnicity White 119 91.5 70 94.6 247 96.5 436 94.8
Other 11 8.5 4 5.4 9 3.5 24 5.2
Socio-economic Current marital status Married/with partner 98 76.6 52 72.2 141 54.9 291 63.7
Single 30 23.4 20 27.8 116 45.1 166 36.3
Marital status (prior disease onset) Married/with partner n/a n/a 56 76.0 115 44.8 171 51.8
Divorced/separated n/a n/a 5 6.7 26 10.1 31 9.4
Single n/a n/a 12 17.3 116 45.1 128 38.8
Education Up to high school 37 28.9 28 38.9 93 36.5 158 34.7
Started HE 13 10.2 11 15.3 40 15.7 64 14.1
Completed HE/PG 78 60.9 33 45.8 122 47.8 233 51.2
Individual income (current) Higher than £19,999 63 51.6 28 43.8 40 16.7 131 30.8
Up to £19,999 59 48.4 36 56.2 199 83.3 294 69.2
Individual income (prior disease onset) Higher than £19,999 n/a n/a 36 56.2 67 28.8 103 34.7
Up to £19,999 n/a n/a 28 43.8 166 71.2 194 65.3
mean SD mean SD mean SD
Index of multiple deprivationa Deciles 5.9 2.6 5.8 2.6 5.8 2.6
(n) (%) (n) (%) (n) (%) (n) (%)
Family health
history
High blood pressure No 69 54.3 39 56.5 116 47.4 224 50.8
Yes 58 45.7 30 43.5 129 52.7 217 49.2
Diabetes No 102 81.0 49 70.0 178 73.6 329 75.1
Yes 24 19.1 21 30.0 64 26.5 109 24.9
Heart problems No 85 68.0 44 62.0 147 59.8 276 62.4
Yes 40 32.0 27 38.0 99 40.2 166 37.6
Asthma No 93 74.4 48 68.6 140 58.3 281 64.6
Yes 32 25.6 22 31.4 100 41.7 154 35.4
Allergies No 72 57.6 49 72.1 98 40.8 219 50.6
Yes 53 42.4 19 27.9 142 59.2 214 49.4
Depression No 80 64.0 48 66.7 132 54.3 260 59.1
Yes 45 36.0 24 33.3 111 45.7 180 40.9
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Table 2 Description of participants from the UK ME/CFS Biobank, by category of recruitment and variables under the following
domains: demographic, socio-economic, family health history, lifestyle, previous morbidity (prior disease onset for the diseased
groups), and recent exposures (Continued)
Domains Variables Category of Recruitment Total
Healthy
control
MS control ME/CFSmm
(n) (%) (n) (%) (n) (%) (n) (%)
Anxiety No 101 80.8 49 70.0 131 54.4 281 64.5
Yes 24 19.2 21 30.0 110 45.6 155 35.6
Mental health problems No 106 84.8 59 83.1 182 75.8 347 79.6
Yes 19 15.2 12 16.9 58 24.2 89 20.4
Learning disabilities No 93 97.9 66 93.0 127 88.2 286 92.3
Yes 2 2.1 5 7.0 17 11.8 24 7.7
Physical disabilities No 88 92.6 62 87.3 120 83.9 270 87.4
Yes 7 7.4 9 12.7 23 16.1 39 12.6
Cancer No 77 61.1 30 41.7 144 60.0 251 57.3
Yes 49 38.9 42 58.3 96 40.0 187 42.7
ME/CFS No 117 94.4 67 97.1 214 89.9 398 92.3
Yes 7 5.7 2 2.9 24 10.1 33 7.7
MS No 94 99.0 60 85.7 137 97.9 291 95.4
Yes 1 1.1 10 14.3 3 2.1 14 4.6
Other neurological problems No 87 91.6 64 90.1 117 83.0 268 87.3
Yes 8 8.4 7 9.9 24 17.0 39 12.7
Tuberculosis No 93 97.9 61 88.4 136 95.8 290 94.8
Yes 2 2.1 8 11.6 6 4.2 16 5.2
Any other health problems No 91 73.4 48 68.6 107 45.7 246 57.5
Yes 33 26.6 22 31.4 127 54.3 182 42.5
Lifestyle median IQR median IQR median IQR
Alcohol consumption Currently (units/week) 4 1 -
10
2 0 - 9 0 0 -
2
n/a n/a
Alcohol consumption Prior disease onset (units/
week)
n/a n/a 3 0 -
10
2 0 -
7
n/a n/a
(n) (%) (n) (%) (n) (%) (n) (%)
Smoking status Never smoke 85 65.4 30 40.5 159 62.1 274 59.6
Ex-smoker 39 30.0 26 35.1 66 25.8 131 28.5
Current smoker 6 4.6 18 24.3 31 12.1 55 12.0
Physical activity level Rather inactive/not active 19 14.6 7 9.5 13 5.1 39 8.5
Neither active nor inactive 23 17.7 11 14.9 23 9.0 57 12.4
Very active/rather active 88 67.7 56 75.7 219 85.9 363 79.1
Previous morbidity High blood pressure No 118 90.8 68 95.8 240 95.2 426 94.0
Yes 12 9.2 3 4.2 12 4.8 27 6.0
Heart problems No 125 96.9 70 98.6 242 96.0 437 96.7
Yes 4 3.1 1 1.4 10 4.0 15 3.3
Asthma No 115 90.6 66 91.7 187 74.2 368 81.6
Yes 12 9.5 6 8.3 65 25.8 83 18.4
Allergies No 67 51.9 49 67.1 143 57.7 259 57.6
Yes 62 48.1 24 32.9 105 42.3 191 42.4
Depression No 113 86.9 57 78.1 157 62.1 327 71.7
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Table 2 Description of participants from the UK ME/CFS Biobank, by category of recruitment and variables under the following
domains: demographic, socio-economic, family health history, lifestyle, previous morbidity (prior disease onset for the diseased
groups), and recent exposures (Continued)
Domains Variables Category of Recruitment Total
Healthy
control
MS control ME/CFSmm
(n) (%) (n) (%) (n) (%) (n) (%)
Yes 17 13.1 16 21.9 96 37.9 129 28.3
Anxiety No 100 76.9 57 78.1 153 60.2 310 67.8
Yes 30 23.1 16 21.9 101 39.8 147 32.2
High levels of stress No 75 57.7 36 50.7 106 42.4 217 48.1
Yes 55 42.3 35 49.3 144 57.6 234 51.9
Frequent coughs/colds No 122 93.9 62 88.6 155 61.8 339 75.2
Yes 8 6.2 8 11.4 96 38.3 112 24.8
Intolerance to alcoholic drinks No 121 94.5 71 100.0 213 88.4 405 92.1
Yes 7 5.5 0 0.0 28 11.6 35 8.0
Intolerance to sugar No 129 99.2 72 100.0 235 94.8 436 96.9
Yes 1 0.8 0 0.0 13 5.2 14 3.1
Other health problems No 111 89.5 60 89.6 166 81.8 337 85.5
Yes 13 10.5 7 10.5 37 18.2 57 14.5
Recent exposures Lived on a farm No 126 96.9 68 95.8 238 94.1 432 95.2
Yes 4 3.1 3 4.2 11 4.4 18 4.0
Don't know 0 0.0 0 0.0 4 1.6 4 0.9
Tick bites No 71 98.6 25 96.2 78 86.7 174 92.6
Yes 0 0.0 0 0.0 1 1.1 1 0.5
Don't know 1 1.4 1 3.9 11 12.2 13 6.9
Vaccines/immunisations No 67 93.1 19 73.1 80 88.9 166 88.3
Yes 5 6.9 7 26.9 8 8.9 20 10.6
Don't know 0 0.0 0 0.0 2 2.2 2 1.1
Travelled overseas No 69 53.1 39 53.4 150 59.3 258 56.6
Yes 61 46.9 31 42.5 87 34.4 179 39.3
Don't know 0 0.0 3 4.1 16 6.3 19 4.2
Flooding No 128 98.5 73 98.7 250 97.7 451 98.0
Yes 2 1.5 1 1.4 3 1.2 6 1.3
Don't know 0 0.0 0 0.0 3 1.2 3 0.7
Radiation No 71 98.6 25 96.2 82 91.1 178 94.7
Yes 1 1.4 1 3.9 4 4.4 6 3.2
0 0.0 0 0.0 4 4.4 4 2.1
Carbon monoxide (CO) No 128 97.7 68 89.5 210 81.4 406 87.3
Yes 1 0.8 0 0.0 3 1.2 4 0.9
Don't know 2 1.5 8 10.5 45 17.4 55 11.8
Pesticides No 119 92.3 57 77.0 174 68.2 350 76.4
Yes 2 1.6 2 2.7 18 7.1 22 4.8
Don't know 8 6.2 15 20.3 63 24.7 86 18.8
Any other chemicals No 118 91.5 54 73.0 158 62.2 330 72.2
Yes 6 4.7 3 4.1 25 9.8 34 7.4
Don't know 5 3.9 17 23.0 71 28.0 93 20.4
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symptom of ME/CFS, and initiate an array of inflamma-
tory responses in ME/CFS [7, 8] that help explain the
pain and other symptoms experienced by people with
ME/CFS. Two studies reveal clustering of cases in UK
schools [36, 37] giving credence to the role of infectious
aetiology in ME/CFS in adolescents/children. Historic-
ally there have been reports of ME-type cluster out-
breaks in adults in defined geographical areas, such as
Los Angeles (poliomyelitis - 1934), Iceland (1948 - Ice-
landic disease), Royal Free Disease, (London, UK 1955 -
benign myalgic encephalomyelitis), Florida (epidemic
neuromyasthenia - 1957), New Zealand (Tapanuni flu
– 1983), Nevada (Lake Tahoe 1984 - chronic fatigue
syndrome). A more recent outbreak in Bergen, Norway
(2004) accounted for cases of ME/CFS-like illness fol-
lowing infection with Giardia enteritis [38]. Assuming
equal exposure risk to common infectious agents for
males and females, with higher female dominance, we
speculate that genotype and the host response, includ-
ing hormonal mediation, are important risk factors.
Our finding that being single or separated/divorced is as-
sociated with ME/CFS may be reverse causal, as ME/CFS
often severely impacts physical health and restricts social
functional ability [39]. Other studies have also found that
participants with ME/CFS are more likely to be unmarried
compared to healthy counterparts [23]. Reverse causality
may also be the reason for lower income reported by
people with ME/CFS, which have previously discussed [39].
Table 2 Description of participants from the UK ME/CFS Biobank, by category of recruitment and variables under the following
domains: demographic, socio-economic, family health history, lifestyle, previous morbidity (prior disease onset for the diseased
groups), and recent exposures (Continued)
Domains Variables Category of Recruitment Total
Healthy
control
MS control ME/CFSmm
(n) (%) (n) (%) (n) (%) (n) (%)
Had meningitis No 130 100.0 73 98.7 247 96.5 450 97.8
Yes 0 0.0 1 1.4 2 0.8 3 0.7
Don't know 0 0.0 0 0.0 7 2.7 7 1.5
Had any other serious infection No 128 98.5 65 89.0 167 67.9 360 80.2
Yes 2 1.5 6 8.2 62 25.2 70 15.6
Don't know 0 0.0 2 2.7 17 6.9 19 4.2
Had any head injury No 129 100.0 65 89.0 229 89.8 423 92.6
Yes 0 0.0 6 8.2 16 6.3 22 4.8
Don't know 0 0.0 2 2.7 10 3.9 12 2.6
Had a major operation No 128 99.2 68 91.9 235 92.2 431 94.1
Yes 1 0.8 6 8.1 15 5.9 22 4.8
Don't know 0 0.0 0 0.0 5 2.0 5 1.1
Contraceptive pill (women only) No 67 52.8 33 45.8 139 55.4 239 53.1
Yes 16 12.6 23 31.9 63 25.1 102 22.7
Don't know 3 2.4 0 0.0 4 1.6 7 1.6
Lived in a house with gas or oil
appliances
No 28 21.5 24 32.9 50 19.8 102 22.4
Yes 102 78.5 49 67.1 201 79.8 352 77.4
Don't know 0 0.0 0 0.0 1 0.4 1 0.2
Lived in a house with a gas fire No 100 77.5 46 63.9 153 61.0 299 66.2
Yes 29 22.5 26 36.1 97 38.7 152 33.6
Don't know 0 0.0 0 0.0 1 0.4 1 0.2
BCG vaccination No 17 17.4 24 32.9 26 17.1 67 20.7
Yes 63 64.3 41 56.2 97 63.8 201 62.2
Don't know 18 18.4 8 11.0 29 19.1 55 17.0
MS – multiple sclerosis; ME/CFS - Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; HE – Higher education; HE/ PG - Higher education/post-graduation;
aIndex of multiple deprivation (IDM) is the measure of relative deprivation for small areas in England (official measure). It is composed by the following indices:
Income Deprivation (22.5%), Employment Deprivation (22.5%), Education, Skills and Training Deprivation (13.5%), Health Deprivation and Disability (13.5%), Crime
(9.3%), Barriers to Housing and Services (9.3%), and Living Environment Deprivation (9.3%). IDM decile 1 refers to the most deprived area and decile 10 to the
least deprived area (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/464430/English_Index_of_Multiple_
Deprivation_2015_-_Guidance.pdf)
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We found an association between reports of family history
of anxiety and ME/CFS, but not with personal history of
anxiety. It has been reported that people with ME/CFS
often have a higher prevalence of psychiatric comorbidities,
primarily depression and anxiety disorder [40], and that
ME/CFS is associated with higher levels of psychological
distress compared with other chronic illness states, such as
rheumatoid arthritis [41]; however we did not find a higher
reported personal history of either depression or anxiety
disorder in people with ME/CFS. We can argue that minor
psychiatric morbidity may well reflect the consequences of
living with a disabling chronic disease. There is inconsist-
ent evidence whether or not primary psychiatric disorder
is a significant risk factor in ME/CFS [40]. One complica-
tion with studies of pre-morbid risk in ME/CFS is that
ME/CFS patients commonly wait many years to get an
affirmative diagnosis, thus studies of pre-diagnostic illness
may be detecting psychopathology secondary to the un-
certainty of a diagnosis, and “unexplained” symptoms. In
addition, given the overlap that exists between the symp-
toms of ME/CFS and psychiatric disorders, (fatigue, low
mood, poor sleep) misdiagnosis may be considerable. In a
study of 279 patients referred to a Belgium clinic with sus-
pected chronic fatigue syndrome, 45.2% were diagnosed
with a mood or anxiety disorder, yet only 23.3% of the
entire cohort eventually received an unequivocal CFS
diagnosis [42]. In a UK study of referrals to a specialist
CFS treatment centre, out of 260 patient referrals exam-
ined, 40% of these did not have CFS but other medical
and psychiatric illnesses [43].
ME/CFS versus MS
ME/CFS cases were shown to be more likely to have
a history of colds and other infections 6 months prior
Table 4 Final multivariable model, comparing participants with ME/CFS and healthy controls (n = 324)
Variables Odds Ratio Standard Error 95% Confidence Interval P value
Age at survey (in years) 1.05 0.01 1.02–1.08 0.003
Lower incomea 3.71 1.18 1.10–6.92 < =0.001
Marital status – separated or divorcedb 1.84 1.02 0.62–5.47 0.275
Marital status – singleb 4.41 1.77 2.00–9.71 <= 0.001
Family history of anxiety 3.77 1.23 1.98–7.16 <= 0.001
History of frequent colds/flu 8.26 3.46 3.64–18-77 <= 0.001
Infection(s) 6 months before disease onset 25.5 20.3 5.33–121.76 0.015
ME/CFS Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
aUp to Up to £19,999/year; bthe refence category is married/with partner, i.e. in a stable relationship
Table 3 List of variables included in the multivariable analyses, by comparison groups and levels of hierarchy
Domain Significant variables resulting from the bivariate analyses, included in the
multivariable models (p ≤ 0.10)
Multivariable analysis 1 – Comparison between people with ME/CFS and healthy controls
Level 1 - Demographic Age at survey, sex, ethnicity
Level 2 - Socio-Economic Marital status, education, income
Level 3 - Family Health History Asthma, allergies, depression, anxiety, learning disabilities, mental health
issues, physical disabilities, other health problems, other neurologic problems
Level 4 - Lifestyle Smoking status, alcohol consumption/week, physical activity previous 6 months
Level 5 - Previous Morbidity (prior to disease onset) Asthma, depression, anxiety, stress, colds, alcohol intolerance, sugar intolerance,
other health problems
Level 6 - Recent Exposures (6 months prior to disease onset) Travelling, pesticides, chemicals, infection(s), pill contraception, surgery(ies),
and gas fire appliances in the home
Multivariable Analysis2 – Comparison between people with ME/CFS and people with MS
Level 1 - Demographic Age at disease onset, sex, ethnicity
Level 2 - Socio-Economic Marital status, education, income, and occupation at 6 months previous onset
Level 3 - Family Health History Allergies, anxiety
Level 4 - Lifestyle Alcohol consumption/week, physical activity previous 6 months
Level 5 - Previous Morbidity (prior to disease onset) Asthma, allergies, depression, anxiety, stress, colds, alcohol intolerance,
sugar intolerance, other health problems
Level 6 - Recent Exposures (6 months prior to disease onset) Infection, BCG vaccine
ME/CFS Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, MS Multiple Sclerosis.
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to disease onset than MS cases; which is consistent
with the findings of comparing ME/CFS with healthy
controls, and with the current theories of predispos-
ing/trigger factors (see section above). Tentative links
have also been made between MS and human herpes
viruses (HHV-6 and EBV) [44]. As in MS, no causal
link between one pathogenic agent and ME/CFS has
been clearly established.
In addition, there was a larger proportion of people liv-
ing with partners among people with MS than in people
with ME/CFS; and lower income was also reported by
people with ME/CFS, which we argue to be explained by
reverse causality. This could also be partially related to the
fact that people with ME/CFS were younger than MS
cases at the time of developing disease symptoms.
Mild-moderate versus severe ME/CFS
Participants with more severe ME/CFS in our cohort
were younger by an average of 4.5 years at disease onset
and were more likely to report a family history of neuro-
logical problems. The association with age and illness se-
verity may reflect the fact that younger sufferers who go
on to have ME/CFS for longer periods, are more likely
to have moderate to severe illness presentations. Norris
et al. report a large-scale follow-up of adolescents with
suspected chronic fatigue syndrome (age 13–18); 75%
spontaneously recover within 2–3 years [45], with a
quarter with persistent disease. In a previous study,
we reported on ME/CFS participants having more
pronounced neuro-cognitive symptoms compared with
MS participants [46]. The association between ME/
CFS and a family history of neurological illness points
to genetic risk factors and/or environmental exposure
risk; such findings require much more detailed inves-
tigation, such as on the confirmation of the diagnosis
in the relative and the inclusion of a more formal
family history investigation with family pedigrees. We
must also consider the ways in which ME/CFS partic-
ipants recount their symptom experience compared
with the ways in which people with MS participants
experience illness; ME/CFS patients often have limited
medical support, whereas MS is a recognised
neurological disease for which there is specialist NHS
support, and this may affect the reliability of the in-
formation reported by the individual.
Strengths and limitations
The presence in the final predictive models of variables
from all the levels defined in the conceptual approach
shows that the occurrence of ME/CFS is the result of a
complex multi-factorial process, which includes fixed
factors such as age and heredity, and variable factors
such as exposure to pathogens. By using a modelling
approach involving different factor domains potentially
associated with ME/CFS, we have been able to present
the relative importance of different risk factors that are
often reported in the literature in isolation. Our multi-
variable analyses helps to capture how different factors
jointly contribute to predict ME/CFS, with some factors
being distal (e.g. age or income) and some factors being
proximal (e.g. recent infection experience). This type of
conceptual approach is useful for theorising ME/CFS
aetiology, but is biased by the selective inclusion and ex-
clusion of factors investigated. Other risk factors not
studied may also be relevant, such as alternative infec-
tious agents, for example. Recall bias is also a major
issue, which is likely to be differential, particularly when
people with ME/CFS are compared to healthy controls.
Data collected from ME/CFS and MS participants relate
to a period before they became ill, and there is no
equivalent period space for healthy controls, making
comparisons challenging between these groups. Never-
theless, healthy control populations offer a reasonable
comparison group. Also, the data result from a survey
where only a small fraction of the individuals reached by
the survey has responded and it is not possible to guar-
antee or ascertain that this is a representative sample of
the targeted population. From the point of view of
model building, the conceptual model selected the
variables in a manner that aimed to reduce the num-
ber of variables in the predictive model; and, by redu-
cing the number of variables we also reduced the
impact of missing values on predictive power. How-
ever, our model did not consider non-linear terms/
Table 5 Final multivariable model, comparing participants with ME/CFS and participants with MS (n = 273)
Variables Odds Ratio Standard Error 95% Confidence Interval P value
Age at disease onset (in years) 0.95 0.02 0.92–0.99 0.016
Lower incomea 3.48 1.27 1.70–7.13 0.001
Marital status – separated or divorcedb 2.26 1.61 0.56–9.12 0.250
Marital status – singleb 3.66 1.62 1.54–8.72 0.003
History of frequent colds/flu 6.31 3.16 2.36–16.86 < 0.001
Infection(s) 6 months before disease onset 5.12 2.97 1.66–15.98 0.005
ME/CFS Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
aUp to Up to £19,999/year; bthe refence category is married/with partner, i.e. in a stable relationship
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interactions and this may be a reason why the good-
ness of fit chi squared test reached significance for
the comparison with MS, and the specificity was very
low (besides the smaller sample size of MS cases in
comparison with the healthy controls).
We believe that if the conceptual model we used in
this study is applied to well-designed prospective cohorts
with larger sample size, some of the limitations de-
scribed would be overcome, and more significant contri-
butions to knowledge of the factors predictive of ME/
CFS could be made.
Conclusions
Our findings suggest a stronger risk association between
exposure to common viral infections (colds/flu) and
ME/CFS than seen in the literature. Additionally, we
found that a recent history of infection prior to disease
onset is associated with ME/CFS. Notable differences in
risk profiles were found between participants with ME/
CFS and healthy controls and ME/CFS and MS. How-
ever, we also found commensurate overlap in some risk
factors between all cohorts. This suggests that while
ME/CFS may share some similar risks with MS, there
are notable differences, particularly the strong associ-
ation with infection in ME/CFS. Our findings add to the
increasing body of evidence on the role infections in the
pathogenesis of ME/CFS.
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